Cerebrospinal fluid biomarkers in Parkinson disease. - Wikidata - wikimedia - TriplyDB

Cerebrospinal fluid biomarkers in Parkinson disease.

Cerebrospinal fluid biomarkers in Parkinson disease.

http://www.wikidata.org/entity/Q38082586

about

Biomarkers of Parkinson's disease: present and future Emerging preclinical pharmacological targets for Parkinson's disease Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease.Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis Alpha-synuclein and tau: teammates in neurodegeneration?Chronic traumatic encephalopathy and other neurodegenerative proteinopathies Predicting parkinsonism: new opportunities from Gaucher disease.CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions Unbiased approaches to biomarker discovery in neurodegenerative diseases Alpha-synuclein levels in blood plasma decline with healthy aging.Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases.Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases Parkinson's disease biomarkers: resources for discovery and validation.Exosomes, an Unmasked Culprit in Neurodegenerative Diseases.Clinical biospecimens: reference materials, certified for nominal properties?Recent developments in biomarkers in Parkinson disease Targeting leucine-rich repeat kinase 2 in Parkinson's disease.Biomarker time out.Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.Oxidized DJ-1 as a possible biomarker of Parkinson's disease Advances in non-dopaminergic treatments for Parkinson's disease Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Psychiatric disturbances regulate the innate immune system in CSF of conscious mice.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.How many biomarkers to discriminate neurodegenerative dementia?The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.

P2860

Q24170134-155A6519-14C5-496D-BFE3-E1544E1ABAB7 Q26764724-150B9AD5-C748-407D-B4C7-0B1330EE2133 Q26767264-455204B0-E424-4409-BFD2-F0D8541AAD9B Q26770708-EEBD8158-0907-4126-BD33-5BBBB64E80D6 Q26785974-529C6D98-CCF5-424F-BCEA-80FC3A5FC7B6 Q27333599-6158662B-8C9A-43F6-BF3F-6E27B31069BE Q28082380-1D2E2081-9FD2-4FEE-82ED-7BD9D08B92A5 Q28250508-B1B9DC1A-026B-47D8-80C0-92F12CDBADB0 Q28395193-590809CC-7D6E-4934-86DB-9E41B0100767 Q30432618-455C2AD9-E93F-4C8D-AD5E-A1B916F4EBA0 Q31144959-C945DFD7-BD91-493C-BD3F-1A38268EB6FD Q33771776-38E183EF-D020-46FC-88D1-FDA6650F793E Q33831118-E5B22F06-00CE-4CF9-860D-7CBD15AD9383 Q33917300-6CB7C3F4-0215-4975-BC69-F4FC69C82A6B Q34118169-739BD991-464C-4C0D-92EF-62F3E76989DA Q34237637-34738785-CC27-47C1-8646-C6F9D1DA9310 Q34625918-53B5A1C2-6070-41A8-BD36-C1EA16169955 Q35284843-465D8003-5DDB-4A0B-8FFE-FA6AF6A559E1 Q35357984-3E5E0AEE-BBA6-4875-AEA5-62F2E0BFC412 Q35772659-AD62C988-2A5A-42E7-BE0D-CFD6F8A2937B Q35857978-5D315BCF-E288-4FEC-9B56-982428903846 Q35969183-879AF613-0E6D-402B-800D-2782EDF35CD1 Q36051094-6F5411DE-DC54-4648-84B5-34F9CC6321A9 Q36535217-E5D8808E-6F2A-45E4-AECB-C8257659BB37 Q36724965-97549825-BA68-4A97-91D5-002B5227D361 Q37053721-07E38906-F2C6-4403-8BA0-A3DDF48AF4B2 Q37379512-205BAA68-21E2-45CC-8668-10A9885AAE58 Q37614565-2F6CCF9C-1166-4D2E-BB73-14E185A44049 Q37716309-F8D93DF2-C072-4309-A441-B103DFAC1C81 Q38119095-3469D66A-F4A2-4CAD-BDA5-E69A6A8A154C Q38160939-DE6DD117-440F-4944-9638-12FB75FC26CA Q38190038-AF588A52-10D7-462B-8327-D7E0A39CAAB1 Q38207538-8B8B9E15-6AA6-4A13-A57C-64706FD41E14 Q38217361-0B373C75-2376-446C-978F-B441FFB8A6EF Q38218083-1316C840-F62A-402F-856D-9301AC6B2259 Q38289739-9CB2DAFE-C78C-44D0-A59B-68476E3C707D Q38517137-4CC3770F-5BB5-43B7-911D-F7AD6F674E3D Q38541943-7ADBC823-7C4B-41FC-BE6A-47BE94889010 Q38570242-498736BC-8BF1-4B48-90E7-85CA5632E347 Q38575114-0D13F8EB-0FA3-464B-8CB9-05827A3B963E

P2860

Cerebrospinal fluid biomarkers in Parkinson disease.

http://www.wikidata.org/entity/Q38082586

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cerebrospinal fluid biomarkers in Parkinson disease.

@en

type

label

Cerebrospinal fluid biomarkers in Parkinson disease.

@en

prefLabel

Cerebrospinal fluid biomarkers in Parkinson disease.

@en

P1433

Q38082586-4CDC371D-E6DA-4D6C-9FFD-85030130AA75

P1476

Q38082586-90DDD524-2F34-4E0D-9132-7485AB7E6E0F

P2093

Q38082586-48388652-1ACE-4CF1-A246-EA166F9C1F27

Q38082586-612C58DD-2A73-46ED-86D3-47331A455D5B

Q38082586-7CDF821E-16D6-4BB1-8120-B3C7B9EF6F77

Q38082586-A4AF5B6C-B765-4D19-8452-B169D263142A

Q38082586-AF951724-DF0D-4C36-A75D-9AABCEE6EFCC

Q38082586-B93895D6-7094-4347-9BC1-B4E734624D58

Q38082586-C7B78430-674C-4960-AC44-5F0EF352CF1F

P2860

Q38082586-009BE01B-6FC0-49B2-AE4C-FA492E39EF99

Q38082586-023F028A-80AF-4730-9E02-BEAEE6FBA2D4

Q38082586-033456D9-8385-4ABC-BF9D-C60AA6E8F700

Q38082586-0362B1E0-2E5A-4886-BB95-B79447B0C470

Q38082586-06BB73C0-7D9B-46F8-917D-C52CFB24597B

Q38082586-07496F5A-44B2-4311-B0AF-1636218CD357

Q38082586-07FB3ED0-8F24-4E68-AC3E-5BBB846825FB

Q38082586-0FC79617-3D0C-492B-BA9F-B8E47DD1ACFA

Q38082586-164CDA5E-DD2B-4D96-905F-D96EEB139E31

Q38082586-17F39BA4-765D-4435-952D-7BD8FA741615

P2888

Q38082586-C82CB96B-B7C4-47E8-8583-70ACA7978EF4

P304

Q38082586-047BB4E5-DA2B-4D3E-BD39-60A5EBC2E845

P31

Q38082586-6EC13EFF-CB3C-4A6D-BAD6-41E696BBBBE6

P356

Q38082586-BF407447-86F9-4CEE-AEC2-B5956D1850DC

P407

Q38082586-9CE312C3-EEA6-4C47-8825-61485493B5D9

P433

Q38082586-192F262D-6D04-40B9-9A69-5C533C5F3409

P478

Q38082586-57D5C813-A74E-4E87-9980-787C977C454D

P577

Q38082586-37B3F080-1BF3-42CD-A587-9BA0906274D5

P5875

Q38082586-BFD47E20-BFA9-4883-BB51-BC4BF1C569EF

P6179

Q38082586-8FBF40AB-C0F7-483F-8C21-EE6E2B31C5A9

P698

Q38082586-2059AA60-ED9D-4FFC-881A-2C308E66A9A7

P921

Q38082586-12CC4AA0-B3FD-42D6-A714-EC041A37FAD7

Q38082586-1A306B63-CE74-4A5A-8C49-15781D27F105

Q38082586-94147DD9-5ADB-40EA-B64B-CE5FC5B95998

P356

NRNEUROL.2013.10

P1433

Nature Reviews Neurology

P1476

Cerebrospinal fluid biomarkers in Parkinson disease.

@en

P2093

Anna Castrioto

http://www.w3.org/2001/XMLSchema#string

Davide Chiasserini

http://www.w3.org/2001/XMLSchema#string

Emanuele Persichetti

http://www.w3.org/2001/XMLSchema#string

Lucilla Parnetti

http://www.w3.org/2001/XMLSchema#string

Nicola Tambasco

http://www.w3.org/2001/XMLSchema#string

Omar El-Agnaf

http://www.w3.org/2001/XMLSchema#string

Paolo Calabresi

http://www.w3.org/2001/XMLSchema#string

P2860

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Genome-wide association study reveals genetic risk underlying Parkinson's disease

Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death

Biochemical premotor biomarkers for Parkinson's disease

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

P2888

nrneurol.2013.10

P304

131-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRNEUROL.2013.10

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235658023

http://www.w3.org/2001/XMLSchema#string

P6179

1018323087

http://www.w3.org/2001/XMLSchema#string

P698

23419373

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

cerebrospinal fluid